Has Rahul Mandiga, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,711 in general payments to Rahul Mandiga, MD across 103 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rahul Mandiga, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rahul Mandiga, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rahul Mandiga, MD

Retina Specialist · Auburn, WANPI 1083800502

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,060 of the $16,711 with a category attached, or 72.2%. Genentech USA, Inc. accounts for 64.4% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $10,470, more than ten times the $274 reported in 2019.

$16,711in general payments, 2019–2025

Across 103 payments — averaging $162.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$11K
Apellis Pharmaceuticals, Inc.$2K
AbbVie$1K
Harrow Eye, LLC$729
Regeneron Healthcare Solutions, Inc.$454
Notal Vision, Inc.$400
plus $987 from 16 others

$450in research payments, 2019–2025

Across 9 payments — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Notal Vision, Inc.$450

What the payments were for

Consulting fees$12,06072%
Speaking & faculty fees$3562%
Travel & lodging$1,1257%
Food & beverage$3,10619%
Education$80%
Gifts$560%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	26	$10,756
Apellis Pharmaceuticals, Inc.	5	$2,226
AbbVie(2 entities)	19	$1,158
Harrow Eye, LLC	4	$729
Regeneron Healthcare Solutions, Inc.	16	$454
Notal Vision, Inc.	4	$400
Novartis	2	$149
Alimera Sciences, Inc.	6	$142
Johnson & Johnson Surgical Vision, Inc.	1	$125
Alcon	2	$112
ANI Pharmaceuticals, Inc.	3	$89
Genentech, Inc.	2	$73
Astellas Pharma US Inc	2	$46
Glaukos Corporation	1	$43
Carl Zeiss Meditec, Inc.	2	$43
Carl Zeiss Meditec AG	2	$39
Eyepoint US, Inc.	1	$34
Topcon Healthcare, Inc.	1	$28
Sun Pharmaceutical Industries Inc.	1	$23
Amgen	1	$17
Spark Therapeutics, Inc.	1	$14
GSK	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$2,501,220

Medicare patients

653

Services billed

35,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	122	$6,257
Difluprednate	14	$1,596
Ketorolac Tromethamine	38	$1,108
Ofloxacin	65	$742
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	50	$563
Brimonidine Tartrate	47	$378
Dorzolamide Hcl	15	$211
Latanoprost	18	$182

Paid to pharmacies, not to this prescriber.

Other retina specialist in Auburn

Minh TrinhAuburn$4K
Benjamin ReissAuburn$2K
George KoRenton$28K
Evelyn FuPuyallup$22K
Himanshu BandaTacoma$15K
Peter ClarkWenatchee$7K
Michael GilbertBellevue$3K
David DruckerSeattle$1K
Brenda Myers PowellFederal Way$422
Kinza AhmadEverett$363

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →